IDEAYA Biosciences (IDYA) Net Income towards Common Stockholders (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$232.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 149.92% year-over-year to -$232.8 million; the trailing twelve-month figure through Mar 2026 stood at -$432.5 million (up 19.34% YoY), and the FY2025 full-year result was -$354.3 million, up 27.94% from the prior year.
• Net Income towards Common Stockholders slipped to -$232.8 million in Q1 2026, from -$94.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $30.2 million in Q3 2025 to a low of -$232.8 million in Q1 2026.
• A 5-year average of -$74.2 million and a median of -$39.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders slumped 379.35% in 2024 and jumped 122.45% in 2025, its largest moves.
• Tracing IDYA's Net Income towards Common Stockholders over 5 years: stood at -$25.3 million in 2022, then plunged by 54.68% to -$39.2 million in 2023, then tumbled by 275.92% to -$147.3 million in 2024, then soared by 35.86% to -$94.5 million in 2025, then sank by 146.43% to -$232.8 million in 2026.
• Business Quant data shows IDYA's Net Income towards Common Stockholders at -$232.8 million in Q1 2026, -$94.5 million in Q4 2025, and $30.2 million in Q3 2025.